Article
European firms beat U.S. on drug access for poor
European drugmakers are better than their U.S. counterparts in ensuring medicines reach people in poor countries, with Britain's GlaxoSmithKline Plc leading the field, according to an analysis on Monday. The ranking -- the first of its kind -- was produced by the Netherlands-based Access to Medicine Foundation and is backed by 12 fund managers, who together manage $1.2 trillion in assets. The ranking is based on eight main criteria, including companies' policies on increasing access, patenting, research into neglected diseases and the use of fair pricing systems...
The full ranking is as follows:
GlaxoSmithKline PLC
Novo Nordisk [part of Novo Group]
Merck & Company Inc
Novartis AG
Sanofi-Aventis
AstraZenica PLC
Roche Holdings Limited
Johnson & Johnson
Bayer Schering Pharma AG [part of Bayer]
Eli Lilly & Company
Bristol-Myers Squibb Comp
Abbott Laboratories Ltd
Merck Kgaa AG
Cipla Limited
Gilead Sciences Inc
Ranbaxy Laboratories Ltd
Pfizer Inc
Wyeth
Teva Pharmaceutical...
Schering-Plough Corp